0 97

Nivolumab in NSCLC: latest evidence and clinical potential

Authors
 Raghav Sundar  ;  Byoung-Chul Cho  ;  Julie R. Brahmer  ;  Ross A. Soo 
Citation
 Therapeutic Advances in Medical Oncology, Vol.7(2) : 85-96, 2015 
Journal Title
 Therapeutic Advances in Medical Oncology 
ISSN
 1758-8340 
Issue Date
2015
Abstract
New insight on the interaction between the immune system and tumor has identified the programmed death-1/programmed death-1 ligand pathway to be a key player in evading host immune response. The immune checkpoint modulator, nivolumab (BMS-936558/ONO-4538), is the first PD-1 inhibitor to gain regulatory approval, for the treatment of patients with unresectable melanoma. This review will discuss results from early phase studies of nivolumab in solid tumors including non-small cell lung cancer (NSCLC) as well as studies of nivolumab in combination with chemotherapy, other immune modulators and molecular targeted therapy in patients with NSCLC.
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/140780
Full Text
http://tam.sagepub.com/content/7/2/85.abstract
DOI
10.1177/1758834014567470
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실)
Yonsei Authors
조병철(Cho, Byoung Chul)
Export
RIS (EndNote)
XLS (Excel)
XML
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse